Last 2,770 INR
Change Today 0.00 / 0.00%
Volume 0.0
DRRD On Other Exchanges
Symbol
Exchange
New York
Natl India
Frankfurt
Mexico
As of 7:05 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
2,746
Previous Close
2,744
Day High
2,795
Day Low
2,721
52 Week High
02/28/14 - 2,940
52 Week Low
08/21/13 - 2,025
Market Cap
471.6B
Average Volume 10 Days
280.4K
EPS TTM
126.52
Shares Outstanding
170.3M
EX-Date
07/11/14
P/E TM
21.9x
Dividend
18.00
Dividend Yield
0.65%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Managing Director, Chief Executi...
Total Annual Compensation: 6.3M
Chairman of the Board, Member of the Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Laboratories Announces the Launch of Duloxetine Delayed-Release Capsules USP

Dr. Reddy's Laboratories announced that it has launched Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg, a therapeutic equivalent generic version of CYMBALTA in the US market on June 26, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration. The CYMBALTA brand and generic had U.S. sales of approximately $5.04 billion MAT for the most recent twelve months ending in April 2014, Dr. Reddy's Duloxetine Delayed-Release Capsules USP 20 mg, 30 mg and 60 mg are available in several bottle counts.

Dr. Reddy's Laboratories Ltd. Launches Paricalcitol Capsules

Dr. Reddy's Laboratories Ltd. announced that it has launched Paricalcitol Capsules, 1 mcg, 2 mcg and 4 mcg, a therapeutic equivalent generic version of ZEMPLAR (Paricalcitol) Capsules in the US market on June 24, 2014, following the approval by USFDA.

Dr Reddy's to Invest in Proprietary Drugs, Initiates Generic Toprol Recall in US

Dr Reddy's announced that the company plans to develop biologics and proprietary medicines and will seek approval for two originator medicines in the United States in 2015. It has already obtained approval to start clinical trials for two biosimilars in the US and in total plans to invest USD 320 million over the next four years to boost its innovative drugs portfolio. Separately, the US Food and Drug Administration has disclosed that Dr Reddy's has started a voluntary recall of 13,560 bottles of its generic version of AstraZeneca's cardiovascular drug Toprol XL (metoprolol succinate). The recall was triggered by the drug's failure in a dissolution test last month.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 2,769.70 INR 0.00

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 440.95 INR 0.00
Endo International PLC $66.97 USD -1.56
Lupin Ltd 1,119 INR 0.00
Ranbaxy Laboratories Ltd 590.25 INR 0.00
Sigma-Aldrich Corp $103.43 USD +0.45
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 21.9x
Price/Sales 3.6x
Price/Book 5.2x
Price/Cash Flow 21.9x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.